NLM-001
- Generic Name
- NLM-001
Study to Evaluate the Safety and Efficacy of Treatment With NLM-001 and Standard Chemotherapy Plus Zalifrelimab in Patients With Advanced Pancreatic Cancer
Phase 1
Active, not recruiting
- Conditions
- Pancreatic Ductal Adenocarcinoma
- Interventions
- First Posted Date
- 2021-04-01
- Last Posted Date
- 2024-12-30
- Lead Sponsor
- Nelum Corp
- Target Recruit Count
- 28
- Registration Number
- NCT04827953
- Locations
- 🇪🇸
Hospital Universitario Virgen De La Victoria, Málaga, Andalucía, Spain
🇪🇸Hospital Universitario Miguel Servet, Zaragoza, Aragón, Spain
🇪🇸Hospital Clínico Universitario de Santiago, Santiago De Compostela, A Coruña, Spain
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath